Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Viacell
Cambridge, Massachusetts, United Statesviacellinc.com ↗
- Ownership
- Private
- Employees
- ~300
- Development stage
- Other
01
Overview
ViaCell was a biotechnology company dedicated to the development of stem cell-based therapies and the provision of umbilical cord blood banking services. The company's primary commercial offering, ViaCord, enabled the preservation of newborn cord blood for potential use in treating various life-threatening diseases. ViaCell also leveraged its proprietary Selective Amplification technology to expand stem cell populations for therapeutic applications, particularly in oncology and hematology. Following its successful growth in the regenerative medicine space, the company was acquired by PerkinElmer in 2007 to bolster their neonatal and prenatal clinical offerings.
- Therapeutic areas
- OncologyRare Diseases
- Modalities
- Stem cell therapyCell therapy
- Industry
- Biotech
02
Partnerships
AmgenGenzyme
Beyond the preview
Go deeper on Viacell.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Viacell.